Diversified clinical-stage immunology company INmune Bio (NASDAQ: INMB) is on a mission to develop
novel immunotherapies that reprogram patients’ innate immune systems to enable
them to fight cancer and Alzheimer’s disease. A recent article further
discussing the company reads, “Innate is an immediate, nonspecific, initial
response that serves as a first line of defense against infection and cancer.
Most drug-development programs concentrate on the adaptive immune response and
ignore innate immunity. INmune Bio harnesses the innate immune system with a
targeted biomarker approach. . . . The company’s INKmune drug is a biologic
therapy. INKmune primes NK cells to eliminate minimal residual disease, which
is a major cause of cancer relapse and death. NK cells play a vital role in
preventing cancer. Later this year, the company expects to begin enrolling
patients in a phase I/II trial for women with relapsed refractory ovarian
cancer.”
To view the full article, visit http://ibn.fm/Yvjtc
About INmune Bio Inc.
INmune Bio Inc. (NASDAQ: INMB) is a publicly traded,
clinical-stage biotechnology company developing therapies targeting the innate
immune system to fight disease. INmune Bio is developing three product
platforms: two products that re-engineer the patient’s innate immune system’s
response to cancer and one product to treat neuroinflammation that is currently
focused on Alzheimer’s disease. INKmune is a natural killer (“NK”) cell
therapeutic that primes the patient’s NK cells to attack minimal residual
disease, the remaining cancer cells that are difficult to detect, which often cause
relapse. INB03 inhibits myeloid derived suppressor cells (“MDSC”), which often
cause resistance to immunotherapy, such as anti-PD-1 checkpoint inhibitors.
XPro1595 targets neuroinflammation, which causes microglial activation and
neuronal cell death. INmune Bio’s product platforms utilize a precision
medicine approach for the treatment of a wide variety of hematologic
malignancies, solid tumors and chronic inflammation. To learn more, please
visit www.INmuneBio.com.
NOTE TO INVESTORS: The latest news and updates
relating to INMB are available in the company’s newsroom at http://ibn.fm/INMB
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
